Featured Story | By Zoey Becker While new polls show flatlining concern about the pandemic among Americans, Moderna's COVID-19 vaccine business continues quietly churning in the background. But amid a recent decline in vaccine demand, the company has written off a sizable chunk of inventory. read more |
| |
|---|
|
Top Stories By Nick Paul Taylor Roche’s business development team has made a busy start to August. On Wednesday, the Swiss pharma company disclosed deals with Poseida Therapeutics and Kiniksa Pharmaceuticals that are together worth $190 million upfront. read more By Robert King The Justice Department is suing Idaho to prevent a near-total abortion ban from going into effect later this month, arguing it conflicts with a federal emergency services law. read more By Andrea Park Siemens' latest earnings push the year’s COVID testing total to about 1.31 billion euros, sending it past the 1.3 billion euro goal it previously set for the year—well ahead of schedule. read more By Fraiser Kansteiner With Libtayo now squarely in Regeneron’s hands, the drugmaker is eager to start cranking out combination therapies. But one near-term prospect is expected to suffer a delay—and armed conflict overseas might be to blame. read more By Annalee Armstrong The pressure is on for Moderna to step up and save the day with a monkeypox vaccine, just as it did for COVID-19. But executives from the famed biotech insist the idea is still in the conceptual phase. read more By Heather Landi Oracle has begun cutting U.S. jobs with workforce reductions primarily impacting marketing and customer experience divisions, according to media reports. Posts on Reddit and thelayoff.com indicate that the workforce reduction is impacting Cerner as well. read more By Conor Hale The deal includes the Oncotype DX GPS test, plus most of Exact Sciences' team of urology sales and marketing professionals. The total cost of the deal could balloon by an additional $70 million if MDxHealth passes revenue milestones through the 2025 fiscal year. read more By Eric Sagonowsky While lawmakers are busy debating details of the reconciliation bill that may take a serious stab at drug prices, pharmaceutical companies are hustling out a defense. One notable point? The legislation wouldn't bring drug price negotiations in Medicare, a prominent pharma CEO said late last week. Instead, it would introduce price controls, he said. read more By Annalee Armstrong It’s going to be a long wait, but RegenXBio is already waving a flag to show that the Hunter syndrome gene therapy RGX-121 is headed for an accelerated approval request at the FDA. read more By Paige Minemyer CVS Health beat the Street in the second quarter with $2.95 billion in profit, according to its earnings report released Wednesday morning. read more By Andrea Park Someone in southwest Ireland must have found a four-leaf clover because the city of Cork has become a lucky recipient of Stryker’s job-creating intentions. read more Resources Sponsored by: Thermo Fisher Scientific See how integration of innovative genetic analysis techniques into drug development is driving biopharma & biotech companies ahead. Sponsored by: Catalent What is the most suitable dosage form technology for the Oral Delivery of Lipid-Based Formulations? Sponsored by: Catalent Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care. Sponsored by: Catalent What are key considerations for intranasal delivery in the treatment of acute and chronic conditions? Sponsored by: Catalent Learn more about how the versatility of Softgel Technology helped a customer with a volatile compound. Sponsored by: Catalent How can Lipid-Based Drug Delivery System help bring poorly soluble drugs to market? Sponsored by: Catalent Carla Vozone discusses the significant trends in the OINDP segment including large molecules and novel indications, changes within CDMOs and various challenges facing the industry. Sponsored by: Catalent Did you know Catalent has newly expanded in-house capabilities spanning clinical and commercial scale manufacturing for DPIs, unit-dose, bi-dose and preserved multi-dose nasal sprays? Sponsored by: Catalent Ypsomed and Catalent Biologics experts discuss strategies for integrated PFS manufacturing and auto-injector assembly to accelerate timelines and more in this webinar. |
|
